New generation specific reverters

File

Idarucizumab Praxbind

Pharmacological Group: Antidote, humanized monoclonal antibody fragment (Fab) for anticoagulant reversal.

Mechanism of Action: It binds specifically and exclusively to the direct oral anticoagulant thrombin inhibitor dabigatran and its active metabolites with an affinity approximately 350 times higher than that of thrombin. By physically coupling to the dabigatran molecule, it immediately neutralizes it, preventing it from continuing to exert its anticoagulant effect on soluble and clot-bound thrombin, without interfering with the host's intrinsic systemic coagulation cascade.

Clinical Pearl: Immediate Coagulation Restoration

After intravenous infusion of idarucizumab, an instantaneous and measurable restoration of clotting times (thrombin time, activated partial thromboplastin time and ecarin time index) is achieved in 99% of patients in the first minute. The effect is persistent over time; However, in patients with residual dabigatran in tissue reservoirs or with severe renal dysfunction, a late re-elevation of free dabigatran may occur at 12-24 hours, requiring a second course of the antidote.

Emergency Dosing of Praxbind

Usual and Single Dose: 5 g full IV, administered in two consecutive vials of 2.5 g each (each vial infused as a 5 to 10 minute bolus or by rapid infusion).
Restart of Anticoagulation: Given that idarucizumab does not intrinsically affect the hemostatic cascade, anticoagulant therapy with dabigatran can be reinstated 24 hours after the bolus, once the focus of acute bleeding has resolved.

Pregnancy: There is insufficient data. Use only in case of lethal obstetric or systemic hemorrhage Breastfeeding: Considered compatible Sugammadex Bridion

Pharmacological Group: Selective reversal agent for neuromuscular blockers, modified cyclodextrin.

Mechanism of Action: It is a modified synthetic gamma cyclodextrin composed of an internal lipophilic ring with 8 negatively charged lateral extensions. It acts molecularly as a selective "encapsulating agent." In plasma, sugammadex specifically binds irreversibly and non-covalently to non-depolarizing steroid-type neuromuscular blockers, especially rocuronium (and with lower affinity vecuronium). By encapsulating the free drug, it immediately shifts the dynamic balance of rocuronium away from the acetylcholine receptors of the neuromuscular motor plate and into the plasma, restoring motor transmission and full spontaneous ventilation to the patient instantly.

Clinical Pearl: Loss of Effectiveness of Oral Contraceptives

A counseling fact of high clinical relevance for post-surgical outpatients: the administration of a therapeutic dose of sugammadex causes a non-specific molecular trapping effect that binds and neutralizes oral hormonal contraceptives (estrogens and progesterone), equivalent to the omission of a daily dose of the pill. It is mandatory to instruct the patient to use an additional barrier contraceptive method (such as a condom) for 7 days after receiving sugammadex.

Dosing Based on Blockage Depth

The dose of sugammadex is not fixed, it is calculated based on the patient's actual body weight and the degree of neuromuscular blockade monitored by train of four (TOF):
1. Routine Reversal (Moderate Blockade - reappearance of T₂ in TOF): 2 mg/kg IV as a rapid bolus.
2. Routine Reversal (Deep Block - 1-2 post-tetanic PT responses): 4 mg/kg IV rapid bolus.
3. Immediate Emergency Reversal (3 min after induction with rocuronium): 16 mg/kg IV as a single direct bolus.
Renal Adjustment: Its use is not recommended in patients with severe renal impairment (ClCr <30 mL/min) due to prolonged elimination of the residual complex.

Pregnancy: Not recommended unless the patient's life is in danger due to respiratory collapse Breastfeeding: Considered compatible